World Asset Management Inc lessened its position in Davita Inc (NYSE:DVA) by 2.4% during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 9,958 shares of the company’s stock after selling 245 shares during the period. World Asset Management Inc’s holdings in Davita were worth $560,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors have also recently modified their holdings of the company. Barings LLC bought a new position in shares of Davita in the first quarter worth approximately $1,568,000. GHP Investment Advisors Inc. lifted its stake in shares of Davita by 1.5% in the first quarter. GHP Investment Advisors Inc. now owns 30,265 shares of the company’s stock worth $1,643,000 after buying an additional 460 shares in the last quarter. Clearbridge Investments LLC lifted its stake in shares of Davita by 63.5% in the first quarter. Clearbridge Investments LLC now owns 798 shares of the company’s stock worth $43,000 after buying an additional 310 shares in the last quarter. Northstar Group Inc. lifted its stake in shares of Davita by 33.2% in the second quarter. Northstar Group Inc. now owns 9,082 shares of the company’s stock worth $511,000 after buying an additional 2,266 shares in the last quarter. Finally, Securian Asset Management Inc lifted its stake in shares of Davita by 1.7% in the first quarter. Securian Asset Management Inc now owns 13,178 shares of the company’s stock worth $715,000 after buying an additional 217 shares in the last quarter. Hedge funds and other institutional investors own 87.65% of the company’s stock.
DVA has been the topic of several analyst reports. Deutsche Bank dropped their target price on shares of Davita from $68.00 to $66.00 and set a “buy” rating on the stock in a research note on Thursday, May 9th. TheStreet upgraded shares of Davita from a “c+” rating to a “b-” rating in a research report on Wednesday, July 24th. Zacks Investment Research upgraded shares of Davita from a “sell” rating to a “hold” rating in a research report on Friday, May 10th. ValuEngine upgraded shares of Davita from a “sell” rating to a “hold” rating in a research report on Monday, July 22nd. Finally, Robert W. Baird downgraded shares of Davita from an “outperform” rating to a “neutral” rating and lowered their price objective for the company from $70.00 to $65.00 in a research report on Friday, July 26th. Eight research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. Davita has a consensus rating of “Hold” and an average target price of $67.06.
Davita stock traded up $0.76 during midday trading on Friday, reaching $60.10. 5,379,970 shares of the company traded hands, compared to its average volume of 2,841,014. The stock has a market cap of $9.87 billion, a price-to-earnings ratio of 16.83, a price-to-earnings-growth ratio of 0.62 and a beta of 1.59. The company’s 50 day simple moving average is $55.99. Davita Inc has a 12 month low of $43.40 and a 12 month high of $79.11. The company has a debt-to-equity ratio of 2.06, a current ratio of 1.12 and a quick ratio of 1.11.
Davita (NYSE:DVA) last issued its quarterly earnings data on Thursday, August 1st. The company reported $1.22 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.10 by $0.12. The company had revenue of $2.84 billion for the quarter, compared to the consensus estimate of $2.86 billion. Davita had a net margin of 1.21% and a return on equity of 14.89%. The firm’s revenue for the quarter was down 1.5% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.05 earnings per share. Sell-side analysts forecast that Davita Inc will post 4.39 earnings per share for the current fiscal year.
DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure or end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also provides outpatient, hospital inpatient, and home-based hemodialysis services; owns clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.
Recommended Story: Percentage Decliners
Want to see what other hedge funds are holding DVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Davita Inc (NYSE:DVA).
Receive News & Ratings for Davita Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Davita and related companies with MarketBeat.com's FREE daily email newsletter.